Last Update 02 Feb 26

CCLD: Cost Discipline And AI Rollout Will Support Future Rerating Potential

Analysts have nudged their price target for CareCloud higher, with some recent research pointing to a range up to US$8. This reflects revised assumptions for cost controls, a flatter near term revenue and EBITDA outlook, and a higher future P/E multiple in their models.

Analyst Commentary

Bullish Takeaways

Bullish analysts see the US$8 price target as supported by tighter cost controls, which they expect to help sustain adjusted EBITDA in the near term even with a flatter revenue outlook.
The higher target range reflects confidence that the market could assign a richer P/E multiple over time, assuming the company maintains its expense discipline.
Following Q3, some bullish analysts updated their models to incorporate revised assumptions on profitability, viewing current levels as not fully reflecting potential execution on cost reductions.
Coverage initiation with a US$8 target indicates that at least part of the Street views current valuation as leaving room for a rerating if the company meets its financial targets.

Bearish Takeaways

Bearish analysts highlight a flattening revenue and EBITDA outlook, which they see as limiting near-term growth and supporting more cautious ratings.
The move to a US$3.25 target in one case, alongside a Neutral stance, suggests some analysts are hesitant to assign a higher P/E multiple without clearer visibility on any potential reacceleration.
There is concern that reliance on cost cuts to support adjusted EBITDA may have limits, which could restrict upside if top-line trends do not improve.
Overall, more cautious analysts appear to align valuation with the view that execution on growth, not just efficiency, will be needed before they consider more constructive ratings.

What's in the News

CareCloud signed Memorial Hospital in Marysville, Ohio to its HealthLine supply chain management platform, expanding use of this Medsphere acquired solution into a community hospital focused on cost control and operational efficiency (Client announcement).
HealthLine is being positioned as a tool to address waste, charge capture, and supply costs, with features such as automated charge capture, mobile scanning, and specialized modules for high value inventory areas (Client announcement).
Affinity Urgent Care selected CareCloud’s Wellsoft emergency department information system, taking the platform into the urgent care segment, which the company describes as one of the fastest growing outpatient access points in the U.S. (Client announcement).
CareCloud completed the full launch of stratusAI Desk Agent, an AI phone receptionist that handles high volume patient calls and integrates with stratusAI Voice Audit to monitor call quality and operational performance (Product announcement).
The company received a Nasdaq notice of non compliance with board independence and audit committee composition rules following the death of independent director John N. Daly. The company reported that it intends to restore compliance by appointing an additional independent director within the allowed cure period that runs to November 24, 2026 or the next annual meeting, whichever comes first (Nasdaq notification).

Valuation Changes

Fair Value: Model fair value remains unchanged at US$6.31. This indicates no revision to the central valuation output in this update.
Discount Rate: The discount rate has risen slightly from 8.36% to 8.43%, implying a modestly higher required return in the updated assumptions.
Revenue Growth: The revenue growth assumption has fallen from 11.10% to 9.88%, reflecting a more conservative view on the pace of future top line expansion.
Net Profit Margin: The net profit margin assumption has declined from 9.47% to 7.31%, pointing to a less optimistic outlook on future profitability levels.
Future P/E: The future P/E multiple has moved higher from 22.73x to 30.47x. This indicates that the updated model applies a richer earnings multiple to CareCloud’s projected results.

6 views

Key Takeaways

Rapid AI-driven automation and new cloud-based solutions are streamlining workflows, driving efficiency, and unlocking access to untapped healthcare segments.
Expanding digital adoption, successful new product launches, and strategic acquisitions are boosting recurring revenues, market reach, and client retention.
Larger tech competitors, regulatory pressures, and rising costs threaten CareCloud's growth, margins, and market position, while expansion into new segments remains uncertain and risky.

Catalysts

About CareCloud

A healthcare information technology (IT) company, provides technology-enabled business solutions, Software-as-a-Service offerings, and related business services to healthcare providers and hospitals primarily in the United States.What are the underlying business or industry changes driving this perspective?

Recent deployment and rapid scaling of AI-driven automation (including cirrusAI Notes and cirrusAI Voice) is streamlining CareCloud's clinical and administrative workflows, reducing manual labor, and enhancing efficiency-positioning the company to expand EBITDA margins and operational leverage in coming quarters.
Full ONC HIT certification for a new, cloud-based, AI-enabled EHR for critical access hospitals opens up access to a largely untapped $1.5 billion rural hospital market segment, which is under pressure to modernize-potentially unlocking a new, durable revenue stream and supporting top-line growth.
Ongoing digital adoption in healthcare and industry momentum behind cloud migration, AI, and automation are driving strong client interest in CareCloud's next-generation intelligent platform, with growing customer adoption rates (notably >75% conversion from trial to paid for cirrusAI Notes), which will likely improve recurring revenues and subscription growth.
Accretive tuck-in acquisitions, enabled by strong free cash flow and an undrawn credit facility, are expanding CareCloud's addressable market, cross-selling opportunities, and average revenue per user, supporting both short-term earnings and long-term revenue growth through broader platform adoption.
Advances in patient engagement tools and upcoming launches such as an AI-powered front desk agent and personal health record platform position CareCloud to benefit from rising demand for connected, interoperable, remote care solutions-driving both incremental revenue and improved client retention in a consolidating healthcare IT market.

CareCloud Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming CareCloud's revenue will grow by 10.3% annually over the next 3 years.
Analysts assume that profit margins will increase from 0.0% today to 20.6% in 3 years time.
Analysts expect earnings to reach $30.9 million (and earnings per share of $0.71) by about September 2028, up from $17.0 thousand today. The analysts are largely in agreement about this estimate.
In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 9.8x on those 2028 earnings, down from 9086.8x today. This future PE is lower than the current PE for the US Healthcare Services industry at 54.8x.
Analysts expect the number of shares outstanding to grow by 7.0% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 7.86%, as per the Simply Wall St company report.

CareCloud Future Earnings Per Share Growth

Risks

What could happen that would invalidate this narrative?

Increasing adoption of AI-driven EHR and revenue cycle management platforms by much larger tech competitors could overshadow CareCloud, resulting in market share erosion and limiting long-term revenue growth.
The company's expansion into the underserved critical access hospital segment and specialty EHR markets is in early stages, with uncertain client uptake and the risk that entrenched legacy providers could impede CareCloud's ability to drive significant new revenue streams.
Substantial investments in AI talent and product development may raise operating costs faster than incremental revenue or margin gains, especially if customer adoption of AI-centric products is slower than anticipated, putting pressure on net margins.
Growing consolidation among payers and providers could shift pricing power and contract terms away from smaller vendors like CareCloud, jeopardizing its ability to maintain or grow revenue and exerting downward pressure on earnings.
Tightening data privacy regulations and evolving interoperability mandates could increase compliance and R&D costs for CareCloud disproportionately compared to larger competitors, limiting its ability to sustain competitive differentiation and potentially compressing margins over time.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $4.75 for CareCloud based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $6.0, and the most bearish reporting a price target of just $2.25.
In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be $150.1 million, earnings will come to $30.9 million, and it would be trading on a PE ratio of 9.8x, assuming you use a discount rate of 7.9%.
Given the current share price of $3.65, the analyst price target of $4.75 is 23.2% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on CareCloud?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Cloud EHR And AI Automation Will Unlock New Opportunities